NeuroPace, Inc. (NASDAQ: NPCE) is a medical technology company headquartered in Mountain View, California, that focuses on the development and commercialization of implantable neuromodulation systems for the treatment of neurological disorders. Founded in 1997, the company’s primary mission is to harness real-time brain data to deliver targeted therapy for patients with drug-resistant epilepsy. NeuroPace has grown from a research-driven startup to a commercial-stage company with a specialized focus on closed-loop neuromodulation.
The company’s flagship product, the RNS® System, is an implantable device that continuously monitors brain activity and delivers electrical stimulation when seizure activity is detected. This responsive neurostimulation technology represents the first and only closed-loop system approved by the U.S. Food and Drug Administration for adults with focal onset seizures who have not achieved seizure control through two or more antiepileptic medications. Clinical studies have demonstrated that the RNS System can significantly reduce seizure frequency and improve quality of life for eligible patients, making it a compelling alternative to open-loop neuromodulation or more invasive surgical interventions.
NeuroPace markets its RNS System directly in the United States, partnering with leading epilepsy centers and specialized neurologists to support patient selection, device implantation, and ongoing follow-up. The company also holds CE Mark approval, enabling limited distribution in select European markets, and is exploring additional partnerships and regulatory pathways to expand its international footprint. Alongside post-market studies, NeuroPace continues research into additional neurological indications that may benefit from closed-loop stimulation, reinforcing its commitment to innovation in neuromodulation.
Under the leadership of President and CEO R. Marc Dunoyer, NeuroPace’s management team and board of directors bring decades of combined experience in neuroscience, medical device development and healthcare commercialization. With an established commercial infrastructure, ongoing clinical trials and a focus on broadening its therapeutic pipeline, NeuroPace aims to advance personalized neurostimulation therapies and extend the benefits of its technology to a wider patient population worldwide.
AI Generated. May Contain Errors.
Free NPCE Stock Alerts